Printer Friendly

Biovail Updates 2005 Guidance; Company Provides Amortization Guidance; Strategic Transaction With Kos Results in Increased EPS Guidance; Diluted EPS Guidance Range Now $1.70 - $1.75 vs. $1.50 - $1.60 Excluding Certain Charges.

TORONTO -- Biovail Corporation (NYSE:BVF)(TSX:BVF) today announced updated financial guidance for 2005 that reflects the impact of the implementation of the first phase of the Company's new Strategic Plan. Earlier this week, Biovail announced the realignment of the Company's commercial operations in the United States; changing the manner in which it commercializes products in the primary-care market of the U.S. and establishing the immediate profitability of that business. As part of that strategic initiative, Biovail will focus its direct selling efforts on specialist physicians, while leveraging established partners in primary-care markets. This strategic realignment carries more modest infrastructure requirements, while providing operational flexibility with regard to expanding into new specialist markets.

As a result of the sale of the Teveten(R) products and the supply agreement for Cardizem(R) LA with Kos Pharmaceuticals, Inc., Biovail is updating overall revenue guidance for 2005 to a range of $860 million to $930 million, down from previous guidance of $925 million to $1 billion. Biovail's significant ongoing interest in Cardizem(R) LA, in conjunction with cost savings associated with the reduction in the Company's U.S. field sales force and operations personnel, results in an updated fully-diluted EPS guidance range of $1.70 - $1.75 (exclusive of certain charges). At the mid-point, the partial year impact of this transaction represents an 11% increase relative to the mid-point of prior guidance, and a 28% increase relative to 2004 diluted EPS (exclusive of certain charges).

As before, Biovail's 2005 guidance does not include the impact of any potential new-product launches, supply-and-distribution agreements or acquisitions; restructuring or other specific charges (see below for information on anticipated charges in the second quarter of 2005); nor does it include expenses related to stock-based compensation.

Biovail's revenue guidance is based on a number of variables, including current prescription and business trends, and the success of our strategic marketing and distribution partners. Wellbutrin XL(R), Biovail's once-daily bupropion formulation which is manufactured and supplied to GlaxoSmithKline (GSK) for the U.S. market, continues to be a key contributor to Biovail's earnings in 2005.

The table below summarizes Biovail's updated revenue guidance for 2005:
----------------------------------------------------------------------
 ($ millions) Q2/2005 Q3/2005 Q4/2005 2005
----------------------------------------------------------------------

Updated Guidance:
Wellbutrin XL(R) 50 - 60 100 - 110 120 - 130 320 - 340
Total Revenues 170 - 210 227 - 267 247 - 287 860 - 930

Previous Guidance:
Wellbutrin XL(R) 50 - 60 110 - 120 120 - 130 320 - 340
Total Revenues 200 - 240 250 - 295 260 - 305 925 - 1,000
----------------------------------------------------------------------


Revenue guidance for Wellbutrin XL(R) remains unchanged at $320 million to $340 million in 2005, with the majority occurring in the second-half of the year. This reflects the timing of shipments and the dynamics of the tiered-pricing agreement with GSK.

Biovail's updated 2005 guidance for gross margins on product sales is 77% to 78%, compared with prior guidance of 78% to 79%. The modest decrease reflects the new supply-and-distribution agreement for Cardizem(R) LA and the sale of the Teveten(R) products to Kos. Gross margins are expected to increase through the second half of 2005, primarily due to product mix driven by higher Wellbutrin XL(R) supply prices.

As a result of the reduction in U.S. commercial operations personnel, and lower advertising and promotional spending (as Kos will now assume this responsibility for the Teveten(R) products and Cardizem(R) LA), Biovail's selling, general and administrative (SG&A) expenses will be positively impacted. These are now anticipated to be in the range of $190 million to $220 million in 2005, down from previous guidance of $300 million to $335 million.

Amortization expense for 2005 is anticipated to be in the range of $60 million to $65 million, and is not included in the SG&A expense guidance figures above.

Biovail will invest some of the cost savings associated with the realignment of the U.S. business to accelerate the Company's product-development pipeline. Accordingly, research-and-development expenses in 2005 are now expected to be in the range of $90 million to $115 million, compared with prior guidance of $80 million to $95 million.

Biovail's updated diluted EPS guidance for 2005 is based on a number of variables and assumptions, including estimated revenues, expenses, gross margins, tax rate, number of shares outstanding and numerous other items as described in the Company's security filings.

Updated diluted EPS for 2005 is expected to be in the range of $1.70 and $1.75. Quarterly EPS guidance for the remainder of 2005 is shown in the table below.
----------------------------------------------------------------------
 Q2/2005 Q3/2005 Q4/2005 2005
----------------------------------------------------------------------

Updated
 Guidance:
EPS(a) $0.22 - $0.26 $0.60 - $0.64 $0.74 - $0.78 $1.70 - $1.75

Previous
 Guidance:
EPS(a) $0.20 - $0.25 $0.55 - $0.60 $0.65 - $0.72 $1.50 - $1.60
----------------------------------------------------------------------

(a) EPS guidance is exclusive of restructuring or other specific
 charges, and does not include stock-based compensation expenses


As a result of the changes to the Company's U.S. commercial operations, Biovail will record a restructuring charge of approximately $20 million to $25 million in the second quarter of 2005, primarily related to severance and other costs associated with a reduction in the number of employees in the U.S. commercial organization. Biovail is currently completing a third-party valuation of the Teveten(R) asset, and a non-cash charge related to the write-down of this asset value, if any, will be recorded in the second quarter of 2005. The $104-million payment received from Kos, net of transaction costs, will be classified as deferred revenue and amortized into product revenues over the seven-year term of the Cardizem(R) LA supply agreement. The remaining net book value of the Teveten(R) asset will be reclassified as a deferred supply cost and will be amortized as an expense through cost of goods sold over the same period.

About Biovail Corporation

Biovail Corporation is a specialty pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacture and commercialization of pharmaceutical products utilizing advanced drug-delivery technologies. For more information about Biovail, visit the company's Web site at www.biovail.com.

For further information, please contact Ken Howling at 905-286-3000 or send inquiries to ir@biovail.com.

"Safe Harbor" Statement Under the Private Securities Litigation Reform Act of 1995

To the extent any statements made in this release contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations and projections about future events. Our actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Forward-looking statements are identified by words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Forward-looking statements include, but are not necessarily limited to, risks and uncertainties, including the difficulty of predicting U.S. Food and Drug Administration and Canadian Therapeutic Products Directorate approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials and finished products, the regulatory environment, tax rate assumptions, the outcome of legal proceedings, fluctuations in operating results and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission and the Ontario Securities Commission. Biovail undertakes no obligation to update or revise any forward-looking statement.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1CANA
Date:May 5, 2005
Words:1260
Previous Article:DENTSPLY International Inc. to Present at Nasdaq's 15th Investor Program, in London, May 19, 2005.
Next Article:American Express Financial Corporation Hires Head of Institutional and Hedge Fund Sales, Client Service and Consultant Relations.
Topics:


Related Articles
Biovail Updates 2004 Financial Guidance.
Biovail Provides 2005 Guidance & Strategy Update.
Biovail Updates 2005 Guidance; Strategic Transaction With Kos Results in Increased EPS Guidance; Diluted EPS Guidance Range Now $1.70 - $1.75 vs....
Biovail Reports Second-Quarter 2005 Financial Results.
Biovail Reports Third-Quarter 2005 Financial Results.
Kos Reports 2005 Fourth Quarter and Full Year Results, Forecasts Continued Double-Digit Revenue Growth for 2006.
Biovail Provides 2006 Guidance.
Biovail Updates 2006 Guidance.
Biovail Provides Financial Update, 2007 Guidance.
Biovail Reports First-Quarter 2007 Financial Results, Plans to File Amended 2006 Form 20-F.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters